A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.
Status:
Completed
Trial end date:
2016-09-26
Target enrollment:
Participant gender:
Summary
This is a Phase I, first-in-human (FIH), randomized, single-blind, placebo-controlled, single
ascending dose sequential group study in healthy male subjects. The objectives are to study
the safety, tolerability, pharmacokinetics and effects on glucose homeostasis
(pharmacodynamics) of AZD9567, an oral differentiated non-steroidal selective glucocorticoid
receptor modulator (SGRM). The study will also assess the safety, tolerability,
pharmacokinetics (PK) and pharmacodynamics (PD) of prednisolone 60 mg in comparison with high
doses of AZD9567 and placebo.